Get the Stockscreener App
40.05
2.69%
1.05
Faeth Therapeutics Inc stock is traded at $40.05, with a volume of 274.97K.
It is up +2.69% in the last 24 hours and up +57.06% over the past month.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
See More
Previous Close:
$39.00
Open:
$38.35
24h Volume:
274.97K
Relative Volume:
1.59
Market Cap:
$1.03B
Revenue:
-
Net Income/Loss:
$-184.46M
P/E Ratio:
-0.2806
EPS:
-142.7277
Net Cash Flow:
$-24.11M
1W Performance:
+18.35%
1M Performance:
+57.06%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$38.35
$41.16
1-Week Range:
$31.75
$41.16
52-Week Range:
$17.50
$41.16
Faeth Therapeutics Inc Stock (FTH) Company Profile
Name
Faeth Therapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
40.05 | 829.48M | 0 | -184.46M | -24.11M | -142.73 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Faeth Therapeutics Inc Stock (FTH) Latest News
FAETH THERAPEUTICS, INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $56 - Bitget
Needham initiates Faeth Therapeutics stock with buy rating on cancer drug potential - Investing.com Canada
FTH Initiates Coverage On by Needham -- Buy Rating with $56 Pric - GuruFocus
Khosla Ventures Seed Associates D, Llc Net Worth (2026) - GuruFocus
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Why is Faeth Therapeutics stock surging today? By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - BioSpace
FDA grants fast track status to Faeth’s endometrial cancer drug - Investing.com
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca - GuruFocus
FDA grants fast track status to Faeth’s endometrial cancer drug By Investing.com - Investing.com Canada
FTH: Faeth Therapeutics, Inc.Insider Transations - Zacks Investment Research
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH) investor Trails Edge reports 2.0% beneficial stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH): Khosla Ventures group discloses 10.2% ownership stake - Stock Titan
Faeth Therapeutics, Inc. (NASDAQ: FTH) Share Price, FTH Stock News, FTH Share Price & Updates - Kalkine
PR News | On the Move: Finn Names Flach PartnerFri., Aug. 14, 2026 - O'Dwyer's PR
Faeth Therapeutics (FTH) investor group reports 0% ownership in amended 13G - Stock Titan
Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments - TradingView
Faeth Therapeutics Adds Senior Leaders Ahead of PIKTOR Clinical Milestones - citybiz
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments - BioSpace
Faeth Therapeutics names two senior vice presidents - Investing.com
Faeth Therapeutics: PI3K Pathway Inhibitor With Key Data Catalyst In Play Intrigues (FTH) - Seeking Alpha
Faeth Therapeutics (FTH) holder files to sell 130K shares under Rule 144 - Stock Titan
Form 144 | Faeth Therapeutics(FTH.US) 10% Stockholder Proposes to Sell 3.64 Million in Common Stocks - Moomoo
FTH Reiterated by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 7, 2026 - BioSpace
H.C. Wainwright Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Faeth Therapeutics Presents Pk/Pd Modeling That Informs Piktor Dose Selection in Ongoing Fth-Pik-201 Trial - marketscreener.com
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - Business Wire
Oppenheimer Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60 - moomoo.com
Faeth Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FTH Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Faeth Therapeutics (FTH) Advances Cancer Research with Merger an - GuruFocus
Faeth Therapeutics, Inc. Q2 2026: Net loss $(16.0M), EPS $(2.84) — 10-Q Summary - TradingView
Faeth Therapeutics Posts $16.0 Million Q2 Net Loss - Quiver Quantitative
Faeth Therapeutics reports $16.0M Q2 net loss, $186.4M cash and marketable securities - TradingView
FTH: Strong cash position and clinical progress with PIKTOR, topline data expected by year-end 2026 - TradingView
FTH: Net loss rose sharply to $186.2M due to acquisition costs; cash reserves stand at $186.4M - TradingView
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates - Business Wire
FAETH THERAPEUTICS, INC : JONESTRADING INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $55 - Bitget
FTH Initiated Coverage by Raymond James -- Rating Set to Outperf - GuruFocus
Faeth Therapeutics, Inc expected to post a loss of $3.62 a shareEarnings Preview - TradingView
Raymond James Initiates Faeth Therapeutics at Outperform - marketscreener.com
Faeth Therapeutics initiated with an Outperform at Raymond James - TipRanks
This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - webull.com
Faeth Therapeutics' Experimental Cancer Drug Piktor Has Upside Potential, Oppenheimer Says - marketscreener.com
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
FTH Initiates Coverage On by Oppenheimer -- Rating Set to Outper - GuruFocus
Faeth Therapeutics, Inc. (FTH) gains Khosla Ventures as reported 10% owner - Stock Titan
Faeth Therapeutics initiated with an Outperform at Oppenheimer - TipRanks
Faeth Therapeutics Inc Stock (FTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Faeth Therapeutics Inc Stock (FTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 30 '26 |
Buy |
24.25 |
7,803 |
189,240 |
41,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jul 01 '26 |
Buy |
23.50 |
5,000 |
117,492 |
46,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 29 '26 |
Buy |
23.34 |
831 |
19,396 |
33,885 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 24 '26 |
Buy |
26.13 |
9,391 |
245,360 |
26,804 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 26 '26 |
Buy |
24.95 |
6,250 |
155,908 |
33,054 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 23 '26 |
Buy |
24.36 |
9,230 |
224,806 |
17,413 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 22 '26 |
Buy |
22.13 |
8,183 |
181,115 |
8,183 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Option Exercise |
1.16 |
53,465 |
62,019 |
817,699 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Buy |
19.76 |
2,806 |
55,447 |
764,234 |
| Cambrian BioPharma Inc | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):